(RTTNews) – Candel Therapeutics, Inc. (CADL), a clinical‑stage biopharmaceutical firm developing multimodal immunotherapies, announced that Martine Zimmermann, PharmD, has been appointed to its board, effective September 8, 2026.
Zimmermann brings over three decades of global regulatory affairs and quality experience spanning all stages of drug development.
She currently serves as Executive Vice President and Head of Regulatory Affairs, Quality and Alliance Management at Inventiva. Prior to that, she led global regulatory affairs and R&D quality at Ipsen Biopharmaceuticals and held senior regulatory leadership positions for more than 13 years at Alexion Pharma.
“Martine joins Candel at a pivotal moment,” said Paul Peter Tak, President and Chief Executive Officer of Candel.
Candel Therapeutics is focused on developing off‑the‑shelf multimodal biological immunotherapies.
Aglatimagene besadenovec is the company’s lead adenovirus‑based candidate, and Linoserpaturev is its lead herpes simplex virus (HSV) candidate.
The company has completed Phase 2a trials of aglatimagene in non‑small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo‑controlled Phase 3 trial of aglatimagene in localized prostate cancer.
Linoserpaturev is currently being evaluated in a Phase 1b trial for recurrent high‑grade glioma.
Upcoming Fourth‑Quarter Milestones
In the fourth quarter, Candel expects to file a Biologics License Application for aglatimagene to treat prostate cancer.
The company anticipates reporting long‑term survival data from Arm C of its Phase 1b study of Linoserpaturev in patients with recurrent high‑grade glioma.
CADL has traded in the range of $4.35 to $14.00 over the past year. Its shares closed at $11.33 on Thursday, down 6.90%.
In after‑hours trading, CADL fell 1.59% to $11.15.
